Trastuzumab halves risk of recurrence of breast cancer in some women
http://www.100md.com
《英国医生杂志》
The result of three trials of trastuzumab (Herceptin) seem to show that the drug, used as adjuvant therapy after surgical treatment of primary breast cancer, halves the recurrence rate of breast cancer in certain women and reduces mortality by 33%.
Two papers published last week summarise the results of three trials—the combined results of the National Surgical Adjuvant Breast and Bowel Project trial plus the North Central Cancer Treatment Group trial, and those of the Herceptin Adjuvant (HERA) trial (New England Journal of Medicine 2005;353:1659-72 and 1673-84)
Both papers find significant benefits for trastuzumab, a therapeutic antibody treatment for women with HER2 positive metastatic breast cancer, a particularly aggressive form of the disease that affects about one in four women with the disease.
The paper on the HERA study (pp 1659-72) shows that using trastuzumab after standard chemotherapy reduces the risk of disease recurrence for women with early stage HER2 positive breast cancer by 46%.
"As compared with observation after primary therapy (including surgery with or without radiotherapy and neoadjuvant or adjuvant chemotherapy), trastuzumab given after primary therapy reduced the rate of recurrence, particularly distant recurrence, by approximately 50%. This degree of benefit in early breast cancer is the largest to be reported since the introduction of tamoxifen in hormone-receptor positive disease," say the authors.
The paper on the joint interim analysis of two phase III trials of trastuzumab plus chemotherapy (pp 1673-84), shows that the addition of the drug reduced the risk of recurrence by 52% in women with early stage, operable HER2 positive breast cancer, compared with women who received chemotherapy alone.
After four years of follow-up, 15% of women treated with trastuzumab plus chemotherapy had a recurrence of breast cancer, compared with 33% of women given chemotherapy alone.
Results from a survival analysis, in the same paper, after a median of 24 months showed a 49% improvement in overall survival, or a hazard ratio of 0.67, equivalent to a 33% reduction in the risk of death.(Abergavenny Roger Dobson)
Two papers published last week summarise the results of three trials—the combined results of the National Surgical Adjuvant Breast and Bowel Project trial plus the North Central Cancer Treatment Group trial, and those of the Herceptin Adjuvant (HERA) trial (New England Journal of Medicine 2005;353:1659-72 and 1673-84)
Both papers find significant benefits for trastuzumab, a therapeutic antibody treatment for women with HER2 positive metastatic breast cancer, a particularly aggressive form of the disease that affects about one in four women with the disease.
The paper on the HERA study (pp 1659-72) shows that using trastuzumab after standard chemotherapy reduces the risk of disease recurrence for women with early stage HER2 positive breast cancer by 46%.
"As compared with observation after primary therapy (including surgery with or without radiotherapy and neoadjuvant or adjuvant chemotherapy), trastuzumab given after primary therapy reduced the rate of recurrence, particularly distant recurrence, by approximately 50%. This degree of benefit in early breast cancer is the largest to be reported since the introduction of tamoxifen in hormone-receptor positive disease," say the authors.
The paper on the joint interim analysis of two phase III trials of trastuzumab plus chemotherapy (pp 1673-84), shows that the addition of the drug reduced the risk of recurrence by 52% in women with early stage, operable HER2 positive breast cancer, compared with women who received chemotherapy alone.
After four years of follow-up, 15% of women treated with trastuzumab plus chemotherapy had a recurrence of breast cancer, compared with 33% of women given chemotherapy alone.
Results from a survival analysis, in the same paper, after a median of 24 months showed a 49% improvement in overall survival, or a hazard ratio of 0.67, equivalent to a 33% reduction in the risk of death.(Abergavenny Roger Dobson)